Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Vagotomy and the risk of mental disorders: A nationwide population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Psychiatric Admissions, Referrals, and Suicidal Behavior Before and During the COVID-19 Pandemic in Denmark: A Time-Trend Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Weight gain on antipsychotics – A perfect storm of complex pathophysiology and psychopharmacology

    Research output: Contribution to journalComment/debateResearchpeer-review

  4. Autism comorbidities show elevated female-to-male odds ratios and are associated with the age of first autism diagnosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Clozapine treatment in a wider context: From before eligibility to life beyond clozapine

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prediction of Early Symptom Remission in Two Independent Samples of First-Episode Psychosis Patients Using Machine Learning

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Glucagon Receptor Antagonist LY2409021 has No Effect on Postprandial Glucose in Type 2 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Vitamin D supplementation improves fasting insulin levels and HDL cholesterol in infertile men

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Schizophrenia is associated with profound cognitive and psychosocial impairments. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for diabetes and obesity treatment, and animal studies have indicated cognitive-enhancing effects. In this investigator-initiated, double-blind, randomized, placebo-controlled trial, we tested non-metabolic effects of exenatide once-weekly (Bydureon™) in obese, antipsychotic-treated patients with schizohrenia spectrum disorder.

METHOD: Before and after 3 months of exenatide (N = 20) or placebo (N = 20) treatment, patients were assessed with the following: Brief Assessment of Cognition in Schizophrenia (BACS), Rey-Osterreith complex figure test (REY), Short-Form Health Survey (SF-36), Personal and Social Performance Scale (PSP) and the Positive and Negative Syndrome Scale (PANSS). We used BACS composite score as the main outcome measure.

RESULTS: Repeated measures analysis of variance on BACS composite score showed significant effect of 'Time' (P < 0.001), no effect of 'Group' (P = 0.64) and no 'Time*Group' interaction (P = 0.77). For REY, SF-36, PSP and PANSS, only significant 'Time' effects were found.

CONCLUSION: The non-significant results of this first clinical trial exploring non-metabolic effects of a long-acting GLP-1RA in patients with schizophrenia could reflect a general problem of translating cognitive-enhancing effects of GLP-1RAs from animals to humans or be explained by factors specifically related to schizophrenia spectrum patients with obesity such as antipsychotic treatment.

Original languageEnglish
Article number1
JournalActa Psychiatrica Scandinavica
Volume136
Issue number1
Pages (from-to)52-62
Number of pages11
ISSN0001-690X
DOIs
Publication statusPublished - Jul 2017

    Research areas

  • Journal Article

ID: 50119900